Business

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision ner

articleAutonomix Medical, Inc.July 21, 20254/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-u-124500061
Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

About this update from Autonomix Medical, Inc.

[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases","length":314,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,295,646 (the ‘646 patent), titled, “Smart Torquer and Methods for Using the Same.” The newly issued ‘646 patent relates to a smart torquer device designed to enhance the manipulation of elongated intravascular devices during minimally invasive procedures, while integrating electronic components to facilitate both mechanical control and data communication.","length":671,"tagName":"p"},{"type":"text","content":"“This patent strengthens our intellectual property portfolio and reinforces our commitment to developing differentiated technologies that address large and underserved markets. The smart torquer improves control and signal integration for intravascular procedures, which is essential for expanding our platform into high-growth areas like cardiology, neurosurgery, and interventional radiology. With the addition of this ‘646 patent to our over 80 issued patents, Autonomix is building a defensible position in a multi-billion-dollar opportunity where precision nerve-targeted interventions can reshape clinical outcomes,” commented Brad Hauser, CEO of Autonomix.","length":663,"tagName":"p"},{"type":"text","content":"In particular, t...

More updates from Autonomix Medical, Inc.

medical device companyintravascular deviceAutonomix Medical, Incchronic pain managementintravascular devicesdata communication